

Oliver N Keene

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7189249/publications.pdf>

Version: 2024-02-01

52
papers

11,379
citations

236925

25
h-index

214800

47
g-index

55
all docs

55
docs citations

55
times ranked

8293
citing authors

#	ARTICLE	IF	CITATIONS
1	Comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma [Respir Med 2020]. <i>Respiratory Medicine</i> , 2022, 191, 106065.	2.9	0
2	From DREAM to REALITY and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 778-797.	5.7	25
3	Estimation of a treatment policy estimand for time to event data using data collected post discontinuation of randomised treatment. <i>Pharmaceutical Statistics</i> , 2022, 21, 612-624.	1.3	1
4	Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1121-1132.e7.	3.8	19
5	Why ITT analysis is not always the answer for estimating treatment effects in clinical trials. <i>Contemporary Clinical Trials</i> , 2021, 108, 106494.	1.8	12
6	Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing. <i>Pharmaceutical Statistics</i> , 2021, 20, 551-562.	1.3	15
7	What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD. <i>Pharmaceutical Statistics</i> , 2020, 19, 370-387.	1.3	14
8	Subgroup Analysis: A View from Industry. <i>Emerging Topics in Statistics and Biostatistics</i> , 2020, , 309-330.	0.1	0
9	Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A <i>Post Hoc</i> Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1308-1312.	5.6	87
10	Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 53.	2.0	25
11	Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥ 300 cells/ μ L. <i>Respiratory Medicine</i> , 2019, 151, 139-141.	2.9	9
12	Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment. <i>Pharmaceutical Statistics</i> , 2019, 18, 85-95.	1.3	8
13	Strategies for composite estimands in confirmatory clinical trials: Examples from trials in nasal polyps and steroid reduction. <i>Pharmaceutical Statistics</i> , 2019, 18, 78-84.	1.3	8
14	Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 980-986.e1.	3.8	60
15	Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 874-882.e4.	3.8	19
16	Biomarkers for severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1509-1518.	2.9	180
17	Estimands: discussion points from the PSI estimands and sensitivity expert group. <i>Pharmaceutical Statistics</i> , 2017, 16, 6-11.	1.3	32
18	Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1167-1175.e2.	2.9	78

#	ARTICLE	IF	CITATIONS
19	Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. <i>Lancet Respiratory Medicine</i> , 2016, 4, 549-556.	10.7	433
20	Number needed to treat: enigmatic results for exacerbations in COPD. <i>European Respiratory Journal</i> , 2016, 47, 353-354.	6.7	1
21	Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 825-826.	2.9	46
22	Missing data sensitivity analysis for recurrent event data using controlled imputation. <i>Pharmaceutical Statistics</i> , 2014, 13, 258-264.	1.3	33
23	Subgroups: Time to Go Back to Basic Statistical Principles?. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 58-71.	0.8	9
24	Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. <i>New England Journal of Medicine</i> , 2014, 371, 1189-1197.	27.0	1,331
25	Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. <i>New England Journal of Medicine</i> , 2014, 371, 1198-1207.	27.0	1,807
26	Number needed to treat in COPD: exacerbations versus pneumonias. <i>Thorax</i> , 2013, 68, 882.1-882.	5.6	5
27	Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2012, 380, 651-659.	13.7	1,849
28	An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 416-424.	2.0	99
29	Statistical resource needs to be increased in the European regulatory agencies. <i>Pharmaceutical Statistics</i> , 2011, 10, 87-88.	1.3	1
30	Intention-to-treat analysis in the presence of off-treatment or missing data. <i>Pharmaceutical Statistics</i> , 2011, 10, 191-195.	1.3	16
31	Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 984-985.	5.6	1
32	Methods for therapeutic trials in COPD: lessons from the TORCH trial. <i>European Respiratory Journal</i> , 2009, 34, 1018-1023.	6.7	24
33	Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. <i>European Respiratory Journal</i> , 2008, 32, 17-24.	6.7	87
34	Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. <i>Pharmaceutical Statistics</i> , 2007, 6, 89-97.	1.3	98
35	Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group. <i>Pharmaceutical Statistics</i> , 2006, 5, 61-66.	1.3	27
36	Inhaled Zanamivir Versus Rimantadine for the Control of Influenza in a Highly Vaccinated Long-term Care Population. <i>Journal of the American Medical Directors Association</i> , 2005, 6, 359-366.	2.5	45

#	ARTICLE	IF	CITATIONS
37	Design and analysis of trials with rare outcomes: Examples from trials in herpes transmission and influenza prophylaxis. <i>Contemporary Clinical Trials</i> , 2005, 26, 311-322.	1.8	0
38	Inhaled Zanamivir Versus Rimantadine for the Control of Influenza in a Highly Vaccinated Long-term Care Population. <i>Journal of the American Medical Directors Association</i> , 2005, 6, 359-366.	2.5	0
39	Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease. <i>New England Journal of Medicine</i> , 2004, 351, 1521-1531.	27.0	2,135
40	Use of generalized estimating equations in a trial in influenza to explore treatment effects over time. <i>Pharmaceutical Statistics</i> , 2004, 3, 281-287.	1.3	4
41	Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. <i>New England Journal of Medicine</i> , 2004, 350, 11-20.	27.0	658
42	Alternatives to the hazard ratio in summarizing efficacy in time-to-event studies: an example from influenza trials. <i>Statistics in Medicine</i> , 2002, 21, 3687-3700.	1.6	27
43	Zanamivir for the Treatment of Influenza A and B Infection in High-Risk Patients. <i>Archives of Internal Medicine</i> , 2001, 161, 212.	3.8	134
44	Diagnosis of Influenza in the Community. <i>Archives of Internal Medicine</i> , 2001, 161, 2116.	3.8	153
45	Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. <i>Pediatric Infectious Disease Journal</i> , 2000, 19, 410-417.	2.0	246
46	Impact of Zanamivir on Antibiotic Use for Respiratory Events Following Acute Influenza in Adolescents and Adults. <i>Archives of Internal Medicine</i> , 2000, 160, 3234.	3.8	96
47	Clinical Efficacy of Inhaled Zanamivir for the Treatment of Patients with Influenza B Virus Infection. <i>Clinical Drug Investigation</i> , 2000, 20, 223-228.	2.2	7
48	Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections. <i>New England Journal of Medicine</i> , 1997, 337, 874-880.	27.0	746
49	The log transformation is special. <i>Statistics in Medicine</i> , 1995, 14, 811-819.	1.6	412
50	Evaluation of different metrics as indirect measures of rate of drug absorption from extended release dosage forms at steady-state. <i>Pharmaceutical Research</i> , 1995, 12, 103-107.	3.5	22
51	Glaxo's Experience of Different Absorption Rate Metrics of Immediate Release and Extended Release Dosage Forms. <i>Drug Information Journal</i> , 1995, 29, 821-840.	0.5	3
52	Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. <i>Drug Information Journal</i> , 1995, 29, 1039-1048.	0.5	232